KEBRIVANT
Glaxo Group Limited
Mark For: KEBRIVANT™ trademark registration is intended to cover the categories of
| Research |
OneLook
Acronym Finder
|
| Serial Number | 88023341 |
| Mark Literal Elements | KEBRIVANT |
| Mark Drawing Type | 4 - STANDARD CHARACTER MARK |
| Mark Type | TRADEMARK |
| Register | PRINCIPAL |
| Current Location | INTENT TO USE SECTION 2021-05-20 |
| Basis | 1(b) |
| Class Status | ACTIVE |
| Primary US Classes |
|
| Primary International Class |
|
| Filed Use | No |
| Current Use | No |
| Intent To Use | Yes |
| Filed ITU | Yes |
| 44D Filed | No |
| 44E Current | No |
| 66A Current | No |
| Current Basis | No |
| No Basis | No |
| Attorney Name | Merilee J. Arevalo |
| Attorney Docket Number | 82664372/eam |
| Law Office Assigned | M10 |
| Employee Name | KHOURI, SANI PHILIPPE |
Timeline
| 2018-07-02 | Application Filed |
| 2018-10-16 | Published |
| 2018-10-16 | Published for Opposition |
| 2018-12-11 | Location: INTENT TO USE SECTION |
| 2019-12-09 | Status: Live/Pending |
| 2019-12-11 | Transaction Date |
| 2021-05-20 | Location: INTENT TO USE SECTION |
| 2021-05-20 | Status: A fifth request for extension of time to file a Statement of Use has been granted. |
Trademark Parties (Applicants & Owners)
| Party: |  Glaxo Group Limited |
| Address | 980 Great West Road Brentford, Middlesex UNITED KINGDOM TW89GS |
| Legal Entity Type | Private Company Limited By Shares (prc) |
| Legal Entity State | ENGLAND |
Documents
Drawing
TEAS Plus New ApplicationAttorney of Record
Good, Services, and Codes
IC 005. US 006 018 044 046 051 052. G & S: Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines |
Trademark Filing History
| Description | Date | Proceeding Number |
|---|---|---|
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2021-05-21 | |
| EXTENSION 5 GRANTED | 2021-05-20 | 71034 |
| CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2021-05-20 | 71034 |
| TEAS EXTENSION RECEIVED | 2021-05-12 | |
| EXTENSION 5 FILED | 2021-05-12 | 71034 |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2020-10-22 | |
| TEAS EXTENSION RECEIVED | 2020-10-20 | |
| EXTENSION 4 GRANTED | 2020-10-20 | 98765 |
| EXTENSION 4 FILED | 2020-10-20 | 98765 |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2020-02-27 | |
| TEAS EXTENSION RECEIVED | 2020-02-25 | |
| EXTENSION 3 GRANTED | 2020-02-25 | 98765 |
| EXTENSION 3 FILED | 2020-02-25 | 98765 |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2019-12-11 | |
| TEAS EXTENSION RECEIVED | 2019-12-09 | |
| EXTENSION 2 GRANTED | 2019-12-09 | 98765 |
| EXTENSION 2 FILED | 2019-12-09 | 98765 |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2019-06-05 | |
| TEAS EXTENSION RECEIVED | 2019-06-03 | |
| EXTENSION 1 GRANTED | 2019-06-03 | 98765 |
| EXTENSION 1 FILED | 2019-06-03 | 98765 |
| NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2018-12-11 | |
| PUBLISHED FOR OPPOSITION | 2018-10-16 | |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2018-10-16 | |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2018-09-26 | |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2018-09-13 | |
| ASSIGNED TO EXAMINER | 2018-09-12 | 77986 |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2018-07-07 | |
| NEW APPLICATION ENTERED IN TRAM | 2018-07-05 |
Similar Marks
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 KEBRIVANT 97129260 not registered Live/Pending |
Glaxo Group Limited 2021-11-17 |
 KEBRIVANT 88023341 not registered Live/Pending |
Glaxo Group Limited 2018-07-02 |
 KEBRIVANT 86501761 not registered Dead/Abandoned |
Glaxo Group Limited 2015-01-13 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 